M. Garassino

发表

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

N. Girard, A. Stenzinger, C. Swanton, 2019 .

C. Swanton, U. Dafni, D. de Ruysscher, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

J. Lunceford, M. Ayers, B. Halmos, 2022, JTO clinical and research reports.

973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC

P. Schwarzenberger, J. Gray, M. Reck, 2022, Annals of Oncology.

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407

J. Lunceford, M. Ayers, Ying Cheng, 2019, Annals of Oncology.

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

H. Mann, M. Hochmair, L. Havel, 2022, ESMO open.

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

P. Jänne, P. Ascierto, P. V. Van Schil, 2020, Annals of Oncology.

OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC

J. Lunceford, M. Ayers, E. Felip, 2019, Journal of Thoracic Oncology.

PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

N. Reinmuth, Y. Shrestha, Haiyi Jiang, 2019, Annals of Oncology.

N. Girard, A. Stenzinger, C. Swanton, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

1318PItalian nivolumab expanded access programme in non-squamous non-small cell lung cancer patients: Real-world results in never smokers and EGFR positive patients

E. Vasile, G. Ceresoli, R. Chiari, 2017 .

Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey

E. Felip, S. Choo, E. Garralda, 2023, ESMO open.

Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies

U. Dafni, E. Felip, J. Tabernero, 2021, ESMO open.

108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)

J. Mazières, A. Delmonte, M. Reck, 2022, Annals of Oncology.

1171MO PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

N. Girard, S. Peters, R. Fietkau, 2021, Annals of Oncology.

122MO Cemiplimab (cemi) + platinum doublet chemotherapy (chemo) + ipilimumab (ipi) for first-line treatment of advanced non-small cell lung cancer (NSCLC): EMPOWER-Lung 3 part I

R. Passalacqua, K. Laktionov, E. Kalinka, 2022, Immuno-Oncology and Technology.

184P Bone-targeted agents (BTA) improve survival in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD-(L)-1 inhibitors (ICIs)

E. Zecca, G. Viscardi, G. Galli, 2021 .

FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189

E. Esteban, S. Gadgeel, J. Gray, 2021 .

79MO PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

N. Girard, S. Siva, A. Allen, 2021 .

1781MO IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer

A. Mansfield, T. Mok, R. Dziadziuszko, 2020 .

P48.03 First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN

N. Reinmuth, Haiyi Jiang, N. Byrne, 2021 .

IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)

N. Reinmuth, Ying Cheng, A. Mansfield, 2019, Annals of Oncology.

OA03.05 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C

P. Paik, J. Mazières, Y. Wu, 2022, Journal of Thoracic Oncology.

LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial

D. Planchard, C. Faivre-Finn, S. Senan, 2020 .

O.03 KEYNOTE-189: OS Update and Progression After the Next Line of Therapy (PFS2) with Pembrolizumab + Chemotherapy for Metastatic Nonsquamous NSCLC

E. Felip, E. Esteban, M. Pietanza, 2019, Journal of Thoracic Oncology.

Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy.

P. Ascierto, A. Rossi, C. Gridelli, 2018, Current clinical pharmacology.

LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

P. Jänne, E. Felip, F. de Marinis, 2022, Immuno-Oncology and Technology.

82ODurvalumab in ≥ 3rd-line EGFR mutant/ALK+, locally advanced or metastatic NSCLC: Results from the phase 2 ATLANTIC study

N. Rizvi, J. Mazières, P. Dennis, 2017 .

1254P Efficacy and safety of tepotinib in patients (pts) with advanced age: VISION subgroup analysis of pts with MET exon 14 (METex14) skipping NSCLC

E. Smit, P. Paik, J. Mazières, 2021, Annals of Oncology.

LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

G. Ostoros, R. Jotte, E. Felip, 2023, Annals of Oncology.